{"id":1168,"date":"2009-02-01T12:01:00","date_gmt":"2009-02-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/ezetimib-cholesterinspiegel-und-malignomrisiko"},"modified":"2009-02-01T12:01:00","modified_gmt":"2009-02-01T11:01:00","slug":"ezetimib-cholesterinspiegel-und-malignomrisiko","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/ezetimib-cholesterinspiegel-und-malignomrisiko","title":{"rendered":"Ezetimib, Cholesterinspiegel und Malignomrisiko"},"content":{"rendered":"<p>Wir haben im April 2008 \u00fcber die verz\u00f6gert und erst unter politischem und \u00f6ffentlichem Druck publizierten negativen Resultate der ENHANCE-Studie berichtet (1). Es handelte sich dabei um eine Studie zum Einfluss des Cholesterinsenkers Ezetimib (in Kombination mit Simvastatin: Inegy\u00ae) auf die Progression der Arteriosklerose bei famili\u00e4rer Hypercholesterin\u00e4mie, in der als Surrogat-Endpunkt eine sonographische Bestimmung der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben im April 2008 \u00fcber die verz\u00f6gert und erst unter politischem und \u00f6ffentlichem Druck publizierten negativen Resultate der ENHANCE-Studie berichtet (1). Es handelte sich dabei um eine Studie zum Einfluss des Cholesterinsenkers Ezetimib (in Kombination mit Simvastatin: Inegy\u00ae) auf die Progression der Arteriosklerose bei famili\u00e4rer Hypercholesterin\u00e4mie, in der als Surrogat-Endpunkt eine sonographische Bestimmung der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2878,451,449,2879,455,453,2880,456,2876,2877,505,443],"class_list":["post-1168","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cholesterin-resorptionshemmer","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-ezetimib","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-improve-it-studie","tag-lipidsenker","tag-seas-studie","tag-sharp-studie","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1168"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1168\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}